Detail akcie Avadel Pharma Rg online

Business Summary: Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Avadel Pharmaceuticals PLC (ADR) revenues increased 67% to $198.1M. Net income totaled $4.8M vs. loss of $43.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest Expense decrease of 14% to $7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.47 to $0.05.